Best Life Sciences Companies in Cincinnati, United States
The 44 best Life Sciences companies in Cincinnati, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Enable Injections.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Cincinnati
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Enable Injections Provider of a wearable drug delivery solution 76Funding top 17%Patents top 23%Innovation top 26%Growth top 26% All 10 signals ▾Fundingtop 17% Patentstop 23% Innovationtop 26% Growthtop 26% Moattop 26% Techtop 42% Markettop 46% Talentbottom 49% Globalbottom 44% Newsbottom 27% Funding: Raised $304M across 10 rounds · 10 rounds over 15 yrs (0.7/yr) Patents: 219 patents matched (strict assignee match) · 109 filings since 2022 vs 93 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $304M | 7 mo ago | Series C | 166 166 → 223 (+34%) | Mike Hooven Founder & CEO | WordPressMySQLPHP+24 | 219 patents Medical injection and fluid handling devices, including transfer, reconstitution, training, and monitoring. | — |
| 2 | CinCor Developer of therapeutics for cardio-renal diseases | $193M | 58 mo ago | Acquired | 15 | Jon Isaacsohn Co-Founder & CEO | — | — | — |
| 3 | CinRx Pharma Developer of therapeutics targeting various conditions to improve clinical outcomes | $176M | 26 mo ago | Series B | 20 | Jonathan Isaacsohn CEO & President | — | — | — |
| 4 | Aerpio Therapeutics Small molecules for the treatment of diabetic macular edema. | $105M | 88 mo ago | Public | 12 | — | — | 373 patents Develops ocular pressure therapies via Tie‑2 activation and hypoxia‑pathway inhibitors. | — |
| 5 | Akebia Therapeutics Developing therapeutics solutions to treat patients with kidney disease | $91M | 30 mo ago | Public | 205 205 → 264 (+29%) | John Butler President and CEO | WordPressApple iCloud MailMySQL+23 | 539 patents Small-molecule pharmaceutical compositions targeting anemia and complement-mediated diseases | — |
| 6 | Airway Therapeutics Provider of protein replacement therapy to prevent and treat lung disease | $38M | 79 mo ago | Series C | 11 11 → 16 (+45%) | — | — | — | — |
| 7 | Standard Bariatrics Provider of medical devices for the surgical treatment of obesity | $36M | 51 mo ago | Acquired | 34 | — | WordPressMySQLPHP+25 | 238 patents Advanced surgical stapling and tissue‑migration control for minimally invasive procedures. | — |
| 8 | P2D Bioscience Developing innovative drugs for central nervous system inflammatory disorders | $21M | 62 mo ago | Funding Raised | — | Prasad Gabbita CEO | — | — | — |
| 9 | Eyas Medical Imaging Developer of an MRI technology for neonatal patients | $16M | 28 mo ago | Series B | 7 | Charles Dumoulin Founder & CTO | — | — | — |
| 10 | Kurome Therapeutics Developer of therapeutics to treat cancer | $15M | 62 mo ago | Series A | 7 | Jan Rosenbaum President | — | — | — |
| 11 | Devicor Medical Advancing breast care through innovative diagnostic and surgical solutions | $14M | 193 mo ago | Acquired | 169 | — | Adobe Experience Manager Edge Delivery ServicesVarnishGoogle Analytics+17 | 1,260 patents Biopsy devices and tissue sampling markers for precise, non‑migrating lesion targeting | — |
| 12 | Onconetix Developer of therapeutics and diagnostics for oncology patients | $7M | 11 mo ago | Public | — | Joseph Hernandez Founder & CEO | WordPressMySQLPHP+13 | — | — |
| 13 | Amplicore Provider of therapeutic solutions for musculoskeletal diseases | $7M | 65 mo ago | Seed | 8 | James Lin Founder | — | — | — |
| 14 | Sus Clinicals Provider of preclinical testing services using pig models | $6M | 35 mo ago | Series A | — | Jeff Weedman CEO | — | — | — |
| 15 | Sense Neuro Diagnostics Non-invasive brain activity monitoring device | $5M | 33 mo ago | Seed | 8 | Geoffrey Klass CEO | WordPressMySQLPHP+19 | — | — |
| 16 | SpineForm Spinal implant designed to help correct and straighten spinal deformities | $3M | 143 mo ago | Deadpooled | — | Joe Reynolds CEO | — | 22 patents Spinal fixation implants and delivery tools for minimally invasive orthopedic surgery. | — |
| 17 | Scientific Data Analysis Platform Provider of data and sequence analysis platform for healthcare researchers | $2M | 19 mo ago | Funding Raised | — | Andrey Kartashov Co-Founder | — | — | — |
| 18 | Blue Ash Therapeutics Developer of drug for cardiovascular disorders | $2M | 196 mo ago | Seed | — | Greg Flexter President | — | — | — |
| 19 | MetaMol Developer of diagnostic and therapeutic strategies to fight the spread of cancer | $399K | 215 mo ago | Funding Raised | — | Georg W Founder and CEO | — | — | — |
| 20 | Open Therapeutics Provider of blockchain-based collaboration platform for life sciences researchers | $180K | 151 mo ago | Deadpooled | — | Jason Barkeloo Founder & Chairman | — | — | — |
| 21 | High Enroll Provider of an app for patient recruitment for clinical trials | $130K | 72 mo ago | Seed | 10 | Dylan Steen Chief Executive Officer and Co-Founder | — | — | — |
Top 12 Life Sciences companies in Cincinnati
#1
Series C · Cincinnati, Ohio · founded 2010 · 166 employees$304.3Mraised▾
Provider of a wearable drug delivery solution. The company's drug delivery device include enFuse for injectable therapies which enables a range of flexible delivery options for patients and healthcare providers, including a range of viscosities, volumes, delivery times, and sites for administration.
- Dec 2025Series C$30M
- Jan 2022Series C$215M
- Sep 2020Conventional Debt$25M
- Oct 2018Series B$50M
#2
Public · Cincinnati, Ohio · founded 2018$7Mraised▾
Developer of therapeutics and diagnostics for oncology patients. The company has developed Entadfi an oral therapeutic for the treatment of benign prostatic hyperplasia a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
- Sep 2025Post IPO$13M
- Oct 2024Post IPO$2M
- Jul 2019Seed$7M
#3
Series B · Cincinnati, Ohio · founded 2015 · 20 employees$176Mraised▾
Developer of therapeutics targeting various conditions to improve clinical outcomes. It utilizes a hub-and-spoke model for identifying and accelerating drug development. It combines scientific, technical, and clinical expertise to guide its portfolio development. The company focuses on developing therapies with the potential to improve quality of life.
- May 2024Series B$73M
- Apr 2024Series A$10M
#4
Public · Cincinnati, Ohio · founded 2007 · 205 employees$91Mraised▾
Developing therapeutics solutions to treat patients with kidney disease. The company's lead candidate is Vafseo is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients.
- Jan 2024Conventional Debt$55M
- Jun 2013Series C$41M
- Apr 2011Series B$22M
- Feb 2011Grant (prize money)$876K
#5
Funding Raised · Cincinnati, Ohio · founded 2015$2.3Mraised▾
Provider of data and sequence analysis platform for healthcare researchers. The company has developed a next-generation data analysis platform that assists researchers and scientists to analyze genomic sequences and more. The platform provides tools for comparative analysis of data, workflow management, and automated prototyping.
- Jan 2025Grant (prize money)$306.5K
- Sep 2020Grant (prize money)$2M
#6
Series B · Cincinnati, Ohio · founded 2014 · 7 employees$15.8Mraised▾
Developer of an MRI technology for neonatal patients. The company provides a small MRI machine to visualize the anatomy of premature and sick babies in neonatal intensive care units without the hazards of ionizing radiation.
- Apr 2024Series B$13.8M
- Dec 2021Series B$10.9M
- Aug 2017Series A$5.8M
#7
Acquired · Cincinnati, Ohio · founded 2018 · 15 employees$193Mraised▾
Developer of therapeutics for cardio-renal diseases. The company's lead candidate is CIN-170 which is an aldosterone synthase inhibitor and works on the renin-angiotensin-aldosterone system (RAAS). It is also involved in the treatment of hypertension, kidney diseases, and others.
- Oct 2021Series B$143M
- May 2019Series A$50M
#8
Public · Cincinnati, Ohio · founded 2011 · 12 employees$104.8Mraised▾
Aerpio Therapeutics focused on the development of therapeutics for vascular disorders with a concentration on diseases of the eye. Lead programs include a Tie-2 activator for diabetic macular edema (DME) and a hypoxia-inducible factor 1-α (HIF1-α) stabilizer for the treatment of inflammatory bowel disease.
- Apr 2019Grant (prize money)$207.3K
- Mar 2017Series C$41.8M
- Nov 2016Conventional Debt$3.5M
- Apr 2016Conventional Debt$4.5M
#9
Acquired · Cincinnati, Ohio · founded 2014 · 34 employees$35.5Mraised▾
Provider of medical devices for the surgical treatment of obesity. The SGS stapling technology has developed STANDARD CLAMP a laparoscopic surgical device designed for the treatment of sleeve gastrectomy.
- May 2022Conventional Debt$7M
- Jun 2021Series B$35M
- Apr 2018Series A—
- Aug 2016Seed—
#10
Seed · Cincinnati, Ohio · founded 2013 · 8 employees$4.6Mraised▾
Sense Diagnostics is a medical device company that develops a non-invasive, disposable device that continuously monitors brain activity primarily in the intensive care unit. Sense Diagnostics uses very low power radio waves to non-invasively detect changes in the amount and location of blood in the brain. The low power RF can detect acute hemorrhage, brain swelling, or seizure. The device consists of three parts: (1) an antenna array, (2) the driving electronics for the array, and (3) a spectrum analyzer coupled with a computer that analyzes the EM signals and detects changes in brain status. It alerts doctors of the growing problems in the brain much sooner than other procedures available.
- Nov 2023Seed$1.1M
- Aug 2021Grant (prize money)$2.4M
- Nov 2020Conventional Debt$545K
- Sep 2019Seed$2.3M
#11
Series A · Cincinnati, Ohio · founded 2020$5.7Mraised▾
Sus Clinicals provides testing services for preclinical solutions using pig models. It performs cancer-related genetic tests using pig models. The company produces its proprietary genetically-modified pig models for preclinical testing. It is used in the identification of drugs, toxicity testing, and diagnostic purpose.
- Sep 2023Grant (prize money)$2M
- Aug 2023Series A$3.7M
#12
Funding Raised · Cincinnati, Ohio · founded 2005$20.8Mraised▾
Developing innovative drugs for central nervous system inflammatory disorders. This specialty pharmaceutical company focuses on creating novel treatments for CNS inflammatory disorders like Frontotemporal Dementia and Alzheimer’s disease. The company utilizes "Targeted Phenotypic Screening" and preclinical models to accelerate drug development. The goal is to advance product candidates through preclinical efficacy testing, safety studies, and early clinical proof-of-concept studies, then seek partners for clinical development and commercialization. The company has a pipeline of orally and centrally active inhibitors for the treatment of FTD and AD, and DAT inhibitors for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). This is a B2B business model.
- 2021Grant (prize money)$844.2K
- 2019Grant (prize money)$580.8K
- 2017Grant (prize money)$583.4K
- 2015Grant (prize money)$3.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Cincinnati researches in biotechnology
- Cincinnati Children\'s Hospital Medical Center22
- University of Cincinnati Medical Center12
- University of Cincinnati6
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.